BUZZ-Foghorn falls after discontinuing independent development of its cancer treatment

Reuters

Dec 16, 2024

BUZZ-Foghorn falls after discontinuing independent development of its cancer treatment

** Shares of drug developer Foghorn Therapeutics FHTX.O fall 37.2% to $3.33 in premarket trading

** Company says it will discontinue independent development of its experimental drug, FHD-286, to be used in combination with chemotherapy medication in patients with a type of blood cancer

** In an early-stage trial, the observed response rate from the drug "did not meet the company's threshold to continue development by Foghorn alone" - FHTX

** Foghorn says it is evaluating partnerships and investigator-sponsored trials to advance FHD-286

** Company expects to report results from the trial at a medical conference in 2025

** Says it will prioritize its proprietary pipeline and Lilly LLY.N collaboration programs

** As of September 30, company had $267.4 mln in cash, cash equivalents and marketable securities; the cash supports the company into 2027 - FHTX

** Up to last close, stock down 17.8% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2491484698"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2491484698\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2491484698?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-16 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491484698","market":"us","top_or_hot":-1,"title":"BUZZ-Foghorn falls after discontinuing independent development of its cancer treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Foghorn falls after discontinuing independent development of its cancer treatment</title></head><body><p>** Shares of drug developer Foghorn <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>FHTX.O</span>  fall 37.2% to $3.33 in premarket trading </p><p>** Company says it will discontinue independent development of its experimental drug, FHD-286, <span>to be used</span> in combination with chemotherapy medication in patients with a type of blood cancer</p><p>** In an early-stage trial, the observed response rate from the drug \"did not meet the company's threshold to continue development by Foghorn alone\" - <span>FHTX</span> </p><p>** Foghorn says it is evaluating partnerships and investigator-sponsored trials to advance FHD-286</p><p>** Company expects to report results from the trial at a medical conference in 2025  </p><p>     ** Says it will prioritize its proprietary pipeline and Lilly <span>LLY.N</span> <span>collaboration programs</span></p><p>** As of September 30, company had <span>$267.4 mln</span> in cash, cash equivalents and marketable securities; the cash supports the company into 2027 - FHTX </p><p>** Up to last close, stock down 17.8% YTD </p><p> (Reporting by Sneha S K)</p><p> ((Sneha.SK@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Foghorn falls after discontinuing independent development of its cancer treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Foghorn falls after discontinuing independent development of its cancer treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-12-16 20:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Foghorn falls after discontinuing independent development of its cancer treatment</title></head><body><p>** Shares of drug developer Foghorn <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>FHTX.O</span>  fall 37.2% to $3.33 in premarket trading </p><p>** Company says it will discontinue independent development of its experimental drug, FHD-286, <span>to be used</span> in combination with chemotherapy medication in patients with a type of blood cancer</p><p>** In an early-stage trial, the observed response rate from the drug \"did not meet the company's threshold to continue development by Foghorn alone\" - <span>FHTX</span> </p><p>** Foghorn says it is evaluating partnerships and investigator-sponsored trials to advance FHD-286</p><p>** Company expects to report results from the trial at a medical conference in 2025  </p><p>     ** Says it will prioritize its proprietary pipeline and Lilly <span>LLY.N</span> <span>collaboration programs</span></p><p>** As of September 30, company had <span>$267.4 mln</span> in cash, cash equivalents and marketable securities; the cash supports the company into 2027 - FHTX </p><p>** Up to last close, stock down 17.8% YTD </p><p> (Reporting by Sneha S K)</p><p> ((Sneha.SK@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nL4N3NH0VV:1","article_id":"2491484698","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491484698","pubTimestamp":1734353328,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Foghorn falls after discontinuing independent development of its cancer treatment** Shares of drug developer Foghorn Therapeutics FHTX.O  fall 37.2% to $3.33 in premarket trading ** Company says it will discontinue independent development of its experimental drug, FHD-286, to be used in combination with chemotherapy medication in patients with a type of blood cancer** In an early-stage trial, the observed response rate from the drug \"did not meet the company's threshold to continue development by Foghorn alone\" - FHTX ** Foghorn says it is evaluating partnerships and investigator-sponsored trials to advance FHD-286** Company expects to report results from the trial at a medical conference in 2025       ** Says it will prioritize its proprietary pipeline and Lilly LLY.N collaboration programs** As of September 30, company had $267.4 mln in cash, cash equivalents and marketable securities; the cash supports the company into 2027 - FHTX ** Up to last close, stock down 17.8% YTD   ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","FHTX":"Foghorn Therapeutics Inc."},"translate_title":"BUZZ-Foghorn停止独立开发癌症治疗药物后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FHTX":0.9},"content_text":"BUZZ-Foghorn falls after discontinuing independent development of its cancer treatment** Shares of drug developer Foghorn Therapeutics FHTX.O  fall 37.2% to $3.33 in premarket trading ** Company says it will discontinue independent development of its experimental drug, FHD-286, to be used in combination with chemotherapy medication in patients with a type of blood cancer** In an early-stage trial, the observed response rate from the drug \"did not meet the company's threshold to continue development by Foghorn alone\" - FHTX ** Foghorn says it is evaluating partnerships and investigator-sponsored trials to advance FHD-286** Company expects to report results from the trial at a medical conference in 2025       ** Says it will prioritize its proprietary pipeline and Lilly LLY.N collaboration programs** As of September 30, company had $267.4 mln in cash, cash equivalents and marketable securities; the cash supports the company into 2027 - FHTX ** Up to last close, stock down 17.8% YTD  (Reporting by Sneha S K) ((Sneha.SK@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}